Bioinformatics analysis of immune‐programmed cell death‐related genes in nasopharyngeal carcinoma
Authors:
Open Access
- 11 June 2025
- journal article
- Published by Wiley in Eye & ENT Research
Abstract
Background: Nasopharyngeal carcinoma (NPC) is a prevalent malignant tumor of the head and neck, characterized by a complex pathogenesis. Most newly diagnosed NPC patients are locally advanced, and 20%–30% of advanced NPC patients have poor immunotherapy results.Purpose: This study aimed to identify key genes associated with immunity and programmed cell death (PCD) in NPC, thereby providing new targets and strategies for precision treatment.Results: In this study, functional annotation and pathway enrichment analysis of differentially expressed genes (DEGs) of GSE12452 and GSE61218 was performed using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Moreover, the search tool for the retrieval of interaction gene/proteins database was constructed to establish a protein‐protein interaction (PPI) network to screen key genes. From GSE12452 and GSE61218, 700 and 619 DEGs were obtained, respectively, and 346 common differential expressed genes (co‐DEGs) were screened. Furthermore, 24 immune‐related common differential expressed genes (IDEGs) were screened by the interaction of co‐DEGs with immune‐related DEGs. The major GO functions enriched for IDEGs were chemokine activity and receptor binding, and KEGG pathways were enriched for cytokine‐cytokine receptor interactions, IL‐17 signaling pathway, chemokine signaling pathway, and so on. PPI analysis identified seven hub genes, including interferon‐gamma (IFNG), CXCL11, CCL8, IL33, Prostaglandin‐endoperoxide synthase 2 (PTGS2), CXCL3, and CXCL14. Remarkably, IFNG and PTGS2 may be the key targets for PCD regulation of NPC immunity.Conclusion: Our results suggest that IFNG and PTGS2 are expected to be new markers and targets for the diagnosis and treatment of NPC, which opens a new way to further improve the prognosis of NPC patients.Keywords
Funding Information
- Natural Science Foundation of Sichuan Province (2025ZNSFSC1783)
This publication has 28 references indexed in Scilit:
- The multifaceted roles of GSDME-mediated pyroptosis in cancer: therapeutic strategies and persisting obstaclesCell Death & Disease, 2023
- Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal CarcinomaJAMA, 2023
- Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)Cancer Cell, 2023
- Lung fibroblasts facilitate pre-metastatic niche formation by remodeling the local immune microenvironmentImmunity, 2022
- Differential Involvement of Programmed Cell Death Ligands in Skin Immune ResponsesJournal of Investigative Dermatology, 2022
- Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trialThe Lancet Oncology, 2021
- Nasopharyngeal carcinomaThe Lancet, 2019
- Ketoconazole exacerbates mitophagy to induce apoptosis by downregulating cyclooxygenase-2 in hepatocellular carcinomaJournal of Hepatology, 2019
- Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trialThe Lancet Oncology, 2016
- Re-Evaluation of 6th Edition of AJCC Staging System for Nasopharyngeal Carcinoma and Proposed Improvement Based on Magnetic Resonance ImagingInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009